新天藥業(002873.SZ):OTC渠道已經覆蓋800餘家連鎖機構,超過13萬家門店
格隆匯12月1日丨新天藥業(002873.SZ)近期在接待機構投資者調研時表示,公司自2018年開始,堅持以“臨牀療效”為抓手,拉動院外零售市場的推廣策略,全面佈局OTC渠道市場。截至目前,OTC渠道已經覆蓋800餘家連鎖機構,超過13萬家門店,且形成了一支專業、穩定的OTC渠道營銷推廣隊伍。
為提高公司產品的市場影響力,實現商業品牌價值,公司於2022年初啟動了商業品牌計劃,在9大中心城市對女性青春與生殖健康管理品牌——“和顏”品牌進行了商業品牌推廣試點。後續我們還將結合試點推廣經驗,擇機將商業品牌計劃推廣至全國市場,逐步實現OTC市場與院內市場的並駕齊驅。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.